Myriad Genetics Inc Sample Contracts

Myriad Genetics Inc – News Release (May 7th, 2019)
Myriad Genetics Inc – News Release (March 14th, 2019)
Myriad Genetics Inc – News Release (February 5th, 2019)
Myriad Genetics Inc – News Release (January 4th, 2019)
Myriad Genetics Inc – MYRIAD GENETICS, INC. (November 30th, 2018)
Myriad Genetics Inc – News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (November 19th, 2018)

SALT LAKE CITY, Nov. 19, 2018 – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the company has entered into an accelerated share repurchase (“ASR”) agreement with Bank of America, N.A. under which the company will repurchase approximately $50 million of its common stock. Myriad currently has approximately $161 million remaining on its existing share repurchase authorization which has been approved by the company’s board of directors.

Myriad Genetics Inc – INDEMNIFICATION AGREEMENT (November 7th, 2018)

THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this ___ day of __________, by and between MYRIAD GENETICS, INC., a Delaware corporation (the “Corporation”), and ___________________________________________________ (“Agent”).

Myriad Genetics Inc – Executive Retention Agreement (November 7th, 2018)

THIS EXECUTIVE RETENTION AGREEMENT (this “Agreement”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and ________________________ (the “Executive”), is made as of ___________, (the “Effective Date”).

Myriad Genetics Inc – News Release (November 6th, 2018)
Myriad Genetics Inc – Myriad Genetics, Inc. Unaudited Pro Forma Condensed Combined Financial Statements (October 15th, 2018)

In connection with the Merger, the Company entered into Amendment No. 1 (the “Amendment”), by and among Myriad, as borrower, the lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Agent”), amending the Credit Agreement, dated as of December 23, 2016 (the “Credit Agreement”). The Amendment effects an “amend and extend” transaction with respect to the Company’s existing senior secured revolving credit facility (the “Facility”) by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million. Other than the extended maturity date and increase in commitment amount, the agreement did not impact or amend the Facility’s previously disclosed terms, including its covenants, events of default, or terms of payment. The proceeds of the Facility were used to (i) finance the acquisition of Counsyl, (ii) pay fees, commissions, transactions costs and expenses incurred in c

Myriad Genetics Inc – December 31, 2017 March 31, 2018 unaudited (In thousands, except share and per share data) ASSETS Current assets: Cash and cash equivalents $ 33,995 $ 23,627 Accounts receivable, less allowance for doubtful accounts of $863 as of December 31, 2017 and $685 as of March 31, 2018 16,232 21,721 Inventory 3,863 3,841 Prepaid expenses and other current assets 3,637 4,599 Total current assets 57,727 53,788 Property and equipment, net 14,133 13,088 Other assets 752 3,067 Total assets $ 72,612 $ 69,943 LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ DEFICIT Current liabilities: A (October 15th, 2018)
Myriad Genetics Inc – Report of Independent Registered Public Accounting Firm (October 15th, 2018)

We have audited the accompanying consolidated balance sheet of Counsyl, Inc. and its subsidiary as of December 31, 2017, and the related consolidated statements of operations and comprehensive loss, of redeemable convertible preferred stock and stockholders’ deficit and of cash flows for the year then ended, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017, and the results of their operations and their cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

Myriad Genetics Inc – CREDIT AGREEMENT dated as of December 23, 2016, and as amended as of July 31, 2018 among (August 24th, 2018)

CREDIT AGREEMENT (this “Agreement”) dated as of December 23, 2016 among MYRIAD GENETICS, INC., a Delaware corporation, the LENDERS from time to time party hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent and as Collateral Agent, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndication Agent, and U.S. BANK NATIONAL ASSOCIATION, PNC BANK, NATIONAL ASSOCIATION, FIFTH THIRD BANK, ZIONS FIRST NATIONAL BANK, a division of ZB, N.A., and SILICON VALLEY BANK, as Co-Documentation Agents.

Myriad Genetics Inc – AGREEMENT AND PLAN OF MERGER by and among (August 24th, 2018)

This Agreement and Plan of Merger (as may be amended from time to time, this “Agreement”) is made and entered into as of May 25, 2018, by and among: Myriad Genetics, Inc., a Delaware Corporation (“Parent”); Cinnamon Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”); Counsyl, Inc., a Delaware corporation (the “Company”); and Fortis Advisors LLC, as the Securityholders’ Representative. Certain capitalized terms used in this Agreement are defined in Exhibit A.

Myriad Genetics Inc – News Release (August 21st, 2018)
Myriad Genetics Inc – News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (August 1st, 2018)

SALT LAKE CITY, July 31, 2018 – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today that it has completed the acquisition of Counsyl, Inc. a leader in reproductive genetic testing based in South San Francisco, Calif.

Myriad Genetics Inc – News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (May 29th, 2018)

SALT LAKE CITY, May 28, 2018 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive agreement to acquire Counsyl, a pioneer in expanded carrier screening and non-invasive prenatal screening for $375 million through a combination of cash and Myriad common stock. Counsyl has experienced rapid growth since being founded in 2007, and in the last twelve months alone has generated more than $134 million in revenue and performed over 280,000 reproductive genetic tests.

Myriad Genetics Inc – News Release (May 8th, 2018)

SALT LAKE CITY, May 8, 2018 – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal third-quarter 2018, provided an update on recent business highlights and raised its fiscal year 2018 financial guidance.

Myriad Genetics Inc – News Release (February 6th, 2018)

SALT LAKE CITY, Feb. 6, 2018 – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal second-quarter 2018, provided an update on recent business highlights, raised its fiscal year 2018 financial guidance, and issued fiscal third-quarter 2018 financial guidance.

Myriad Genetics Inc – MYRIAD GENETICS, INC. 2013 EXECUTIVE INCENTIVE PLAN (December 1st, 2017)
Myriad Genetics Inc – MYRIAD GENETICS, INC. (December 1st, 2017)
Myriad Genetics Inc – News Release (November 7th, 2017)
Myriad Genetics Inc – News Release (November 2nd, 2017)
Myriad Genetics Inc – News Release (September 5th, 2017)
Myriad Genetics Inc – News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (May 2nd, 2017)

SALT LAKE CITY, UTAH, May 2, 2017 – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal third-quarter 2017, provided an update on recent business highlights and updated its fiscal year 2017 financial guidance.

Myriad Genetics Inc – CREDIT AGREEMENT dated as of December 23, 2016 among MYRIAD GENETICS, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A. as Administrative Agent and Collateral Agent WELLS FARGO BANK, NATIONAL ASSOCIATION as Syndication Agent and U.S. BANK NATIONAL ASSOCIATION, PNC BANK, NATIONAL ASSOCIATION, FIFTH THIRD BANK, ZIONS FIRST NATIONAL BANK, a division of ZB, N.A., and SILICON VALLEY BANK as Co-Documentation Agents JPMORGAN CHASE BANK, N.A. and WELLS FARGO SECURITIES, LLC as Joint Bookrunners and Joint Lead Arrangers (February 8th, 2017)

CREDIT AGREEMENT (this “Agreement”) dated as of December 23, 2016 among MYRIAD GENETICS, INC., a Delaware corporation, the LENDERS from time to time party hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent and as Collateral Agent, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndication Agent, and U.S. BANK NATIONAL ASSOCIATION, PNC BANK, NATIONAL ASSOCIATION, FIFTH THIRD BANK, ZIONS FIRST NATIONAL BANK, a division of ZB, N.A., and SILICON VALLEY BANK, as Co-Documentation Agents.

Myriad Genetics Inc – News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (February 7th, 2017)

SALT LAKE CITY, UTAH, Feb. 7, 2017 – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal second-quarter 2017, provided an update on recent business highlights, updated its fiscal year 2017 financial guidance and issued fiscal third-quarter 2017 financial guidance.

Myriad Genetics Inc – MYRIAD GENETICS, INC. 2010 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN, AS AMENDED (as amended on December 1, 2016) (December 2nd, 2016)
Myriad Genetics Inc – UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS (November 14th, 2016)

On August 31, 2016, Myriad Genetics, Inc. (“Myriad” or the “Company”) completed the acquisition of privately-held Assurex Health, Inc. (“Assurex”), pursuant to the Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”), dated August 3, 2016. Pursuant to the terms of the Merger Agreement, Myriad acquired Assurex by means of a reverse triangular merger in which the Merger Subsidiary will merge with and into Assurex, with Assurex surviving the merger as the surviving corporation and a wholly owned subsidiary of Myriad (the “Merger”).

Myriad Genetics Inc – INDEX TO CONSOLIDATED FINANCIAL STATEMENTS As of December 31, 2014 and 2015 and June 30, 2016 (unaudited) and the years ended December 31, 2014 and 2015 and six months ended June 30, 2015 and 2016 (unaudited) (November 14th, 2016)

We have audited the accompanying consolidated balance sheets of Assurex Health, Inc. and Subsidiary as of December 31, 2014 and 2015, and the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock, non-controlling interest and shareholders’ deficit, and cash flows for each of the two years in the period ended December 31, 2015. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

Myriad Genetics Inc – CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (November 14th, 2016)
Myriad Genetics Inc – AGREEMENT AND PLAN OF MERGER among: MYRIAD GENETICS, INC. a Delaware corporation; MYRIAD MERGER SUB, INC., a Delaware corporation; ASSUREX HEALTH, INC., a Delaware corporation; and FORTIS ADVISORS LLC, as the Securityholders’ Agent Dated as of August 3, 2016 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. (November 2nd, 2016)

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of August 3, 2016, by and among MYRIAD GENETICS, INC., a Delaware corporation (“Parent”); MYRIAD MERGER SUB, INC., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”); ASSUREX HEALTH, INC., a Delaware corporation (the “Company”); and FORTIS ADVISORS LLC, a Delaware limited liability company, as the Securityholders’ Agent (as defined in Section 11.1(a)). Certain capitalized terms used in this Agreement are defined in Exhibit A.

Myriad Genetics Inc – MYRIAD GENETICS, INC. Executive Retention Agreement (November 2nd, 2016)

THIS EXECUTIVE RETENTION AGREEMENT (this “Agreement”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Virginia C. Drosos (the “Executive”), is made as of September 26, 2016 (the “Effective Date”).

Myriad Genetics Inc – CREDIT AGREEMENT dated as of August 31, 2016 among MYRIAD GENETICS, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A. as Administrative Agent JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead Arranger (November 2nd, 2016)

CREDIT AGREEMENT (this “Agreement”) dated as of August 31, 2016 among MYRIAD GENETICS, INC., a Delaware corporation, the LENDERS from time to time party hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent.

Myriad Genetics Inc – INDEMNIFICATION AGREEMENT (November 2nd, 2016)

THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this 26th day of September, 2016, by and between MYRIAD GENETICS, INC., a Delaware corporation (the “Corporation”), and Virginia C. Drosos (“Agent”).